NCT02266927View on ClinicalTrials.gov

A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2)

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

April 30, 2015

Conditions
Mild to Moderate Asthma
Interventions
DRUG

Flovent HFA

DRUG

OPTINOSE™ FLUTICASONE

Trial Locations (1)

BT9 6AD

Celerion, Belfast

All Listed Sponsors
lead

Optinose US Inc.

INDUSTRY

NCT02266927 - A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2) | Biotech Hunter | Biotech Hunter